On 16 and 17 May, the Euro-PAD initiative held a scientific symposium in Amsterdam, aimed to discuss the latest developments in neuroimaging and biomarkers for Alzheimer’s disease. This year, the event began with two imaging workshops on the advancements in Positron Emission Tomography (PET) and advanced Magnetic Resonance Imaging (MRI) quantification.

The first afternoon of the symposium officially commenced with a warm welcome from Frederik Barkhof and Lyduine Collij, establishing a collaborative atmosphere for the event. Over 70 participants attended the meeting in person, highlighting the strong interest and commitment within the scientific community. The opening session featured an overview of the Euro-PAD initiative, highlighting the substantial progress made over the past year. The symposium’s agenda was packed with insightful scientific sessions covering key topics such as the use of Amyloid-PET in the clinical routine and trials, advancements in disease modelling and MRI-PET analysis. Additionally, on the second day, sessions covered topics on imaging/genetics and developments in fluid biomarkers.

Euro-PAD continues the pioneering efforts of the AMYPAD pan-European collaborative framework, integrating several major cohorts including EPAD, AMYPAD, ALFA+, Prevent-AD and Microbiota. This year, new cohorts were introduced, including the T-POT study, Insight-preAD, SCIENCe and REALAD, reflecting the consortium’s expanding scope. The two-day event was marked by lively discussions where delegates had the opportunity to present their latest results, share insights and explore potential collaborations.